Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Peritoneal Neoplasms. Found 13 abstracts

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-91.   PMCID: PMC5715461
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther. 2015 Jan;16(12):1726-37.   PMCID: PMC4847814
Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2014 Mar;132(3):526-30.   PMCID: 4469031
Thomay AA, Nagorney DM, Cohen SJ, Sigurdson ER, Truty MJ, Burtness B, Hall MJ, Chun YS. Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer. J Gastrointest Surg. 2014 Jan;18(1):69-74.
Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr;129(1):86-91.   PMCID: PMC 3712785
Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.   PMCID: PMC 2668552
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7.   PMCID: PMC 2741166
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
Coukos G, Courreges MC, Benencia F. Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm. Curr Gene Ther. 2003 Apr;3(2):113-25.
Baser ME, De Rienzo A, Altomare D, Balsara BR, Hedrick NM, Gutmann DH, Pitts LH, Jackler RK, Testa JR. Neurofibromatosis 2 and malignant mesothelioma. Neurology. 2002 Jul 23;59(2):290-1.
Montgomery RC, Hoffma JP, Ross EA, Riley LB, Ridge JA, Eisenberg BL. Biliary CA 19-9 values correlate with the risk of hepatic metastases in patients with adenocarcinoma of the pancreas. J Gastrointest Surg. 1998 Jan;2(1):28-35.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Peritoneal Neoplasms

Peritoneal Neoplasms Female Aged Middle Aged Adult Ovarian Neoplasms 80 and over Aged drug therapy therapeutic use Fallopian Tube Neoplasms adverse effects Local Neoplasm Recurrence Disease-Free Survival pathology Male Antineoplastic Combined Chemotherapy Protocols Glandular and Epithelial Neoplasms Human administration & dosage metabolism Neoplasm Staging Carboplatin Survival Rate Paclitaxel secondary therapy genetics analogs & derivatives analysis blood Lung Neoplasms immunology Liver Neoplasms Monoclonal Antibodies Young Adult Immunohistochemistry surgery derivatives chemically induced Antineoplastic Agents Mutation US Gov't Support-PHS administration & chemistry Colorectal Neoplasms dosage antagonists & inhibitors Her2 Acneiform Eruptions precision medicine analogs & Lymph Nodes Retrospective Studies effects irinotecan Hepatectomy Inflammation virology Cohort Studies molecular profiling Adolescent Prognosis Niacinamide Neoplasm Drug Resistance Kaplan-Meier Estimate High-Throughput Nucleotide Sequencing Retreatment Intravenous Infusions Neoplasm DNA Protein Kinase Inhibitors Neurofibromin 2 Cancer Vaccines BRCA1 Protein BRCA2 Genes Diarrhea Bile Cytoreduction Surgical Procedures Mesothelioma Neurofibromatosis 2 Platinum Compounds Case Report Protein-Tyrosine Kinases BRCA1 Genes Fluorescence In Situ Hybridization diagnosis Simplexvirus Dendritic Cells analogs & Topotecan Non-US Gov't Support Cytokines Angiogenesis Inhibitors BRCA2 Protein physiology Drug Dose-Response Relationship Germ-Line Mutation Fatigue Vascular Endothelial Growth Factor A Gene Amplification Risk Factors Hypotension Middle Age Fatal Outcome Monoclonal Antibodies-Humanized Toxicity Gene Expression Profiling CA-19-9 Antigen Ovarian cancer Camptothecin Veliparib Polyglutamic Acid Cox2 Kras Type II DNA Topoisomerases metastasis pharmacokinetics Phase II trial Doxorubicin Forecasting Biological Tumor Markers Benzimidazoles Topo1 Lymphatic Metastasis PARP inhibitor Glial Cell Line-Derived Neurotrophic Factor Deoxycytidine Immunoconjugates Braf Gene Therapy BRCA2 mutation BRCA1 Mice Nausea Folate Receptor 1 Pancreatic Neoplasms c-MET Tumor Biomarkers Indoles Response Evaluation Criteria in Solid Tumors colorectal cancer Drug Interactions Follow-Up Studies oxaliplatin Drug Administration Schedule Apc Vision Disorders Proteomics Polyethylene Glycols Tp53 Ercc1 peritoneal cancer
Last updated on Wednesday, February 05, 2020